NHSA (prev. SMIA)

Explore the landscape of NHSA (prev. SMIA) in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on NHSA (prev.  SMIA) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Policy / Regulatory

China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices

Policy / Regulatory

Chinese Authorities Launch Special Campaign to Combat Fraud in Medical Insurance

Policy / Regulatory

China’s NHSA Introduces Tiered Pricing for COVID-19 Therapies: A, B, and C Categories

HospitalPolicy / Regulatory

NHSA Launches Crackdown on Medical Insurance Fund Management with New Inspection Measures

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Policy / Regulatory

NHSA’s 2022 Healthcare Security Report Reveals Break-Even Performance

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Policy / Regulatory

NHSA Releases Guidelines on Drug Procurement and Pricing Management

Show More